vs
碧迪（BDX）与Envista Holdings Corp（NVST）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Envista Holdings Corp的7.0倍（$5.3B vs $750.6M）。碧迪净利率更高（7.3% vs 4.4%，领先2.9%）。Envista Holdings Corp同比增速更快（15.0% vs -0.4%）。碧迪自由现金流更多（$549.0M vs $91.7M）。过去两年Envista Holdings Corp的营收复合增速更高（9.7% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Envista Holdings Corp是一家总部位于美国的企业，旗下Envista Forensics业务板块面向保险、法律及风险管理行业，在全球范围内提供法务工程与事故复原解决方案。公司前身为LWG咨询有限公司，2017年正式更名为Envista Forensics。
BDX vs NVST — 直观对比
营收规模更大
BDX
是对方的7.0倍
$750.6M
营收增速更快
NVST
高出15.3%
-0.4%
净利率更高
BDX
高出2.9%
4.4%
自由现金流更多
BDX
多$457.3M
$91.7M
两年增速更快
NVST
近两年复合增速
2.0%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $750.6M |
| 净利润 | $382.0M | $32.9M |
| 毛利率 | 45.9% | 54.7% |
| 营业利润率 | 10.5% | 9.8% |
| 净利率 | 7.3% | 4.4% |
| 营收同比 | -0.4% | 15.0% |
| 净利润同比 | 24.0% | 2641.7% |
| 每股收益（稀释后） | $1.34 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXNVST
| Q4 25 | $5.3B | $750.6M | ||
| Q3 25 | $5.9B | $669.9M | ||
| Q2 25 | $5.5B | $682.1M | ||
| Q1 25 | $5.3B | $616.9M | ||
| Q4 24 | $5.2B | $652.9M | ||
| Q3 24 | $5.4B | $601.0M | ||
| Q2 24 | $5.0B | $633.1M | ||
| Q1 24 | $5.0B | $623.6M |
净利润BDXNVST
| Q4 25 | $382.0M | $32.9M | ||
| Q3 25 | $493.0M | $-30.3M | ||
| Q2 25 | $574.0M | $26.4M | ||
| Q1 25 | $308.0M | $18.0M | ||
| Q4 24 | $303.0M | $1.2M | ||
| Q3 24 | $400.0M | $8.2M | ||
| Q2 24 | $487.0M | $-1.2B | ||
| Q1 24 | $537.0M | $23.6M |
毛利率BDXNVST
| Q4 25 | 45.9% | 54.7% | ||
| Q3 25 | 47.5% | 55.3% | ||
| Q2 25 | 47.8% | 54.2% | ||
| Q1 25 | 42.8% | 54.5% | ||
| Q4 24 | 43.2% | 57.1% | ||
| Q3 24 | 45.7% | 52.8% | ||
| Q2 24 | 46.2% | 51.6% | ||
| Q1 24 | 45.7% | 57.1% |
营业利润率BDXNVST
| Q4 25 | 10.5% | 9.8% | ||
| Q3 25 | 11.8% | 8.6% | ||
| Q2 25 | 16.0% | 6.8% | ||
| Q1 25 | 10.4% | 6.3% | ||
| Q4 24 | 8.8% | 7.1% | ||
| Q3 24 | 11.4% | 3.5% | ||
| Q2 24 | 12.1% | -182.2% | ||
| Q1 24 | 14.5% | 7.7% |
净利率BDXNVST
| Q4 25 | 7.3% | 4.4% | ||
| Q3 25 | 8.4% | -4.5% | ||
| Q2 25 | 10.4% | 3.9% | ||
| Q1 25 | 5.8% | 2.9% | ||
| Q4 24 | 5.9% | 0.2% | ||
| Q3 24 | 7.4% | 1.4% | ||
| Q2 24 | 9.8% | -181.9% | ||
| Q1 24 | 10.6% | 3.8% |
每股收益（稀释后）BDXNVST
| Q4 25 | $1.34 | $0.20 | ||
| Q3 25 | $1.71 | $-0.18 | ||
| Q2 25 | $2.00 | $0.16 | ||
| Q1 25 | $1.07 | $0.10 | ||
| Q4 24 | $1.04 | $0.00 | ||
| Q3 24 | $1.37 | $0.05 | ||
| Q2 24 | $1.68 | $-6.69 | ||
| Q1 24 | $1.85 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.2B |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $25.3B | $3.1B |
| 总资产 | $54.8B | $5.7B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资BDXNVST
| Q4 25 | $740.0M | $1.2B | ||
| Q3 25 | $641.0M | $1.1B | ||
| Q2 25 | $735.0M | $1.1B | ||
| Q1 25 | $667.0M | $1.1B | ||
| Q4 24 | $711.0M | $1.1B | ||
| Q3 24 | $1.7B | $991.3M | ||
| Q2 24 | $4.5B | $1.0B | ||
| Q1 24 | $2.3B | $948.5M |
总债务BDXNVST
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益BDXNVST
| Q4 25 | $25.3B | $3.1B | ||
| Q3 25 | $25.4B | $3.1B | ||
| Q2 25 | $25.5B | $3.1B | ||
| Q1 25 | $25.2B | $3.0B | ||
| Q4 24 | $25.2B | $2.9B | ||
| Q3 24 | $25.9B | $3.1B | ||
| Q2 24 | $25.9B | $3.0B | ||
| Q1 24 | $25.6B | $4.1B |
总资产BDXNVST
| Q4 25 | $54.8B | $5.7B | ||
| Q3 25 | $55.3B | $5.6B | ||
| Q2 25 | $54.9B | $5.7B | ||
| Q1 25 | $54.5B | $5.5B | ||
| Q4 24 | $54.7B | $5.4B | ||
| Q3 24 | $57.3B | $5.5B | ||
| Q2 24 | $55.6B | $5.4B | ||
| Q1 24 | $54.2B | $6.6B |
负债/权益比BDXNVST
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.46× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $108.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $91.7M |
| 自由现金流率自由现金流/营收 | 10.5% | 12.2% |
| 资本支出强度资本支出/营收 | 2.1% | 2.2% |
| 现金转化率经营现金流/净利润 | 1.72× | 3.28× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $230.4M |
8季度趋势，按日历期对齐
经营现金流BDXNVST
| Q4 25 | $657.0M | $108.0M | ||
| Q3 25 | $1.4B | $78.7M | ||
| Q2 25 | $1.2B | $88.7M | ||
| Q1 25 | $164.0M | $300.0K | ||
| Q4 24 | $693.0M | $132.4M | ||
| Q3 24 | $1.2B | $70.7M | ||
| Q2 24 | $1.3B | $93.1M | ||
| Q1 24 | $514.0M | $40.3M |
自由现金流BDXNVST
| Q4 25 | $549.0M | $91.7M | ||
| Q3 25 | $1.0B | $67.9M | ||
| Q2 25 | $1.0B | $76.4M | ||
| Q1 25 | $35.0M | $-5.6M | ||
| Q4 24 | $588.0M | $123.8M | ||
| Q3 24 | $882.0M | $63.3M | ||
| Q2 24 | $1.1B | $86.3M | ||
| Q1 24 | $380.0M | $29.3M |
自由现金流率BDXNVST
| Q4 25 | 10.5% | 12.2% | ||
| Q3 25 | 17.0% | 10.1% | ||
| Q2 25 | 19.0% | 11.2% | ||
| Q1 25 | 0.7% | -0.9% | ||
| Q4 24 | 11.4% | 19.0% | ||
| Q3 24 | 16.2% | 10.5% | ||
| Q2 24 | 22.4% | 13.6% | ||
| Q1 24 | 7.5% | 4.7% |
资本支出强度BDXNVST
| Q4 25 | 2.1% | 2.2% | ||
| Q3 25 | 6.0% | 1.6% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 2.0% | 1.3% | ||
| Q3 24 | 5.4% | 1.2% | ||
| Q2 24 | 3.6% | 1.1% | ||
| Q1 24 | 2.7% | 1.8% |
现金转化率BDXNVST
| Q4 25 | 1.72× | 3.28× | ||
| Q3 25 | 2.75× | — | ||
| Q2 25 | 2.12× | 3.36× | ||
| Q1 25 | 0.53× | 0.02× | ||
| Q4 24 | 2.29× | 110.33× | ||
| Q3 24 | 2.94× | 8.62× | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | 1.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
NVST
| Other | $375.8M | 50% |
| Specialty Productsand Technologies | $188.4M | 25% |
| Equipmentand Consumables | $186.4M | 25% |
